XML 179 R102.htm IDEA: XBRL DOCUMENT v3.26.1
Discontinued operations - Results of discontinued operation (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disclosure of analysis of single amount of discontinued operations [line items]      
Revenue $ 92,390 $ 15,936 $ 6,155
Direct costs (43,600) (6,659) (4,982)
Gross profit 48,790 9,277 1,173
Other income and other net gains 614 2,006 4,133
Selling and marketing expenses (35,540) (5,413) (5,462)
Research and development expenses (5,132) (9,051) (9,172)
Impairment loss of goodwill (6,815) 0 0
Administrative and other operating expenses (46,398) (33,090) (29,116)
Operating loss from continuing operations (44,481) (36,271) (38,444)
Share of loss of equity-accounted investees, net of tax (1,260) (2,010) (670)
Other finance costs (241) (168) (46)
Loss before taxation (36,213) (46,025) (42,944)
Income tax credit 22 235 440
Loss from discontinued operations, net of tax $ (3,731) $ (11,420) $ (21,779)
Loss per share      
Basic (in US Dollar per share) $ (0.23) $ (0.57) $ (1.79)
Diluted (in US Dollar per share) $ (0.23) $ (0.57) $ (1.79)
Prevention and diagnostics - COVID-19 related and EMEA operations      
Disclosure of analysis of single amount of discontinued operations [line items]      
Income tax credit $ 0 $ 0 $ 117
Loss from discontinued operations, net of tax $ 3,141 $ 20 $ (8,377)
Loss per share      
Basic (in US Dollar per share) $ 0.22 $ 0 $ (0.74)
Diluted (in US Dollar per share) $ 0.22 $ 0 $ (0.74)
ACT genomics      
Disclosure of analysis of single amount of discontinued operations [line items]      
Income tax credit $ 22 $ 235 $ 323
Loss from discontinued operations, net of tax $ (6,872) $ (11,442) $ (13,402)
Loss per share      
Basic (in US Dollar per share) $ (0.45) $ (0.57) $ (1.05)
Diluted (in US Dollar per share) $ (0.45) $ (0.57) $ (1.05)
Discontinued operations      
Disclosure of analysis of single amount of discontinued operations [line items]      
Revenue $ 9,605 $ 14,782 $ 29,050
Direct costs (5,435) (8,601) (15,288)
Gross profit 4,170 6,181 13,762
Other income and other net gains 5,034 785 664
Selling and marketing expenses (2,215) (3,223) (3,413)
Research and development expenses (1,266) (1,872) (3,679)
Impairment loss of goodwill 0 0 (3,900)
Administrative and other operating expenses (10,636) (13,722) (25,268)
Operating loss from continuing operations (4,913) (11,851) (21,834)
Share of loss of equity-accounted investees, net of tax (868) 231 (189)
Gain on disposal of a subsidiary 2,045 0 0
Other finance costs (17) (35) (196)
Loss before taxation (3,753) (11,655) (22,219)
Discontinued operations | Prevention and diagnostics - COVID-19 related and EMEA operations      
Disclosure of analysis of single amount of discontinued operations [line items]      
Revenue 0 97 13,462
Direct costs 0 (39) (7,357)
Gross profit 0 58 6,105
Other income and other net gains 4,590 46 290
Selling and marketing expenses 0 (2) (632)
Research and development expenses 0 0 (1,189)
Administrative and other operating expenses (1,449) (82) (12,946)
Operating loss from continuing operations 3,141 20 (8,372)
Other finance costs 0 0 (122)
Loss before taxation 3,141 20 (8,494)
Discontinued operations | ACT genomics      
Disclosure of analysis of single amount of discontinued operations [line items]      
Revenue 9,605 14,685 15,588
Direct costs (5,435) (8,562) (7,931)
Gross profit 4,170 6,123 7,657
Other income and other net gains 444 739 374
Selling and marketing expenses (2,215) (3,223) (2,781)
Research and development expenses (1,266) (1,872) (2,490)
Impairment loss of goodwill 0 0 (3,900)
Administrative and other operating expenses (9,187) (13,640) (12,322)
Operating loss from continuing operations (8,054) (11,873) (13,462)
Share of loss of equity-accounted investees, net of tax (868) 231 (189)
Gain on disposal of a subsidiary 2,045 0 0
Other finance costs (17) (35) (74)
Loss before taxation $ (6,894) $ (11,677) $ (13,725)